Thermo Fisher Scientific (TMO) Cash & Current Investments (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash & Current Investments for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 36.4% year-over-year to $4.1 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (down 36.4% YoY), and the FY2025 full-year result was $10.1 billion, up 81.42% from the prior year.
• Cash & Current Investments advanced to $4.1 billion in Q2 2026 per TMO's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $10.1 billion in Q4 2025 and bottomed at $1.9 billion in Q3 2022.
• Historically, Cash & Current Investments has averaged $5.5 billion across 5 years, with a median of $5.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments sank 75.73% in 2022, then jumped 181.62% in 2024.
• Over 5 years, Cash & Current Investments stood at $8.5 billion in 2022, then retreated by 5.21% to $8.1 billion in 2023, then plunged by 31.06% to $5.6 billion in 2024, then jumped by 81.42% to $10.1 billion in 2025, then plunged by 59.78% to $4.1 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.1 billion, $3.3 billion, and $10.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.